News, Resources, Updates
A scientific hub to keep you informed about our latest research and company updates.
InnoSer Partners with Kabuki Syndrome Foundation to Advance Therapeutic Development for Kabuki Syndrome
InnoSer to serve as the central hub for Kabuki Syndrome Foundation-funded preclinical research in the Kmt2d+/βGeo mouse model. This collaboration aims to empower leading biotech and pharma innovators to perform rigorous studies informing clinical trial readiness of...
InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025
We are excited to announce that InnoSer, as an innovative European preclinical neurodegenerative disease CRO, will be actively participating in the upcoming ADPD 2025 conference, taking place in Vienna, Austria from 1st to 5th April 2025. The ADPD 2025 Conference is...
Top 4 Multi-Organ-on-a-Chip TissUse Assays and Why You Should Include them in Your Preclinical Research in 2025
Preclinical research is evolving rapidly, and staying ahead means embracing innovative tools that streamline processes and provide actionable insights. Multi-Organ-on Chip (MOC) assays, also known as microphysiological systems (MPS), are among the most exciting...
InnoSer Strengthens Neurology Platform with Acquisition of remynd’s CRO Business
InnoSer’s acquisition of remynd’s CRO business further strengthens its neurology platform by integrating specialized neurodegenerative mouse models, expanding its service portfolio for Alzheimer’s and Parkinson’s diseases. Diepenbeek, Belgium – March 4th – InnoSer, a...
Multiplex Cytokine and Immune Cell Profiling in Immuno-Oncology Research
The Meso-Scale Discovery (MSD) platform is a high-sensitivity, multiplex cytokine profiling analysis system, enabling you to simultaneously quantify multiple target cytokines, chemokines, antibodies, and growth factors from minute sample volumes (as low as 1 µL). By...
Targeted Gene Therapy Preclinical Testing Approaches in the ADPKD Mouse Model
With several recent gene therapy approvals in space and more on the horizon, the field of rare genetic diseases is experiencing a transformative era. The field of rare genetic kidney diseases, including ADPKD remains no exception to this, with gene therapy emerging as...
info@innoserlaboratories.com

![InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025](https://www.innoserlaboratories.com/wp-content/uploads/2025/03/ADPD-2025-InnoSer-Neurodegenerative-Disease-Models-400x250.png)



